Search Results
Jul 23, 2026, 10:31 ET ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
eligible for ALK-targeted treatments. Enhanced early and precise diagnosis is further contributing to the growth of the market.Growing Focus on CNS Disease Control: Brain metastases frequently occur in patients with ALK-positive NSCLC, driving the need for therapies that provide effective control
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 08:30 ET ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
month at the Alzheimer's Association International Conference (AAIC), where more than 140 presentations and posters featured data from the NULISAseq CNS Disease 120, Neuro 220, and AD 5-plex panels or NULISAqpcr BD-pTau217 single plex assays which incorporate ALZpath's proprietary pTau217 antibody.About
More news about: ALZpath, Inc.
Jul 23, 2026, 08:05 ET Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced the launch of two denosumab biosimilars—OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)—expanding access to more
More news about: Accord BioPharma
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
functional improvement in the muscle in a DM1 model, and these new preclinical data highlight the effects seen in the CNS, and the platform's potential to address both muscle and CNS diseases.About ARTHEx BiotechARTHEx Biotech is a clinical-stage company developing targeted RNA medicines
More news about: ARTHEx Biotech
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
functional improvement in the muscle in a DM1 model, and these new preclinical data highlight the effects seen in the CNS, and the platform's potential to address both muscle and CNS diseases.About ARTHEx BiotechARTHEx Biotech is a clinical-stage company developing targeted RNA medicines
More news about: ARTHEx Biotech
Jul 22, 2026, 10:31 ET CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight
(Kite) announced that the US FDA approved an update to YESCARTA labeling, removing the prior limitation of use in patients with relapsed or refractory primary CNS lymphoma (PCNSL), reinforcing its safety profile and making it the only CAR T-cell therapy with this restriction removed for large B-cell lymphoma.In
More news about: DelveInsight Business Research, LLP
Jul 22, 2026, 09:25 ET China Pharma Announces Pricing of $5 Million Registered Direct Offering
markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable
More news about: China Pharma Holdings, Inc.
Jul 22, 2026, 07:00 ET Curis Announces Positive Emavusertib Update
Wednesday, July 22 at 8:30 a.m. ET to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary CNS Lymphoma (PCNSL), and provide updated guidance on year-end data in the TakeAim CLL study, its ongoing Phase 2 study in Chronic Lymphocytic Leukemia (CLL).
More news about: Curis, Inc.
Jul 22, 2026, 06:50 ET Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma
biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered
More news about: Neurimmune
Jul 21, 2026, 16:00 ET China Pharma Holdings, Inc. Comments on Unusual Market Activity
markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable
More news about: China Pharma Holdings, Inc.
Jul 21, 2026, 10:05 ET Clinicians Report That Summit 2.0™ Influenced Clinical Decision-Making in 86% of Cases; 96% Stated They Would Order the Test Again
2.0 CSF-based genomic testing influenced clinical decision-making across a range of CNS disease contexts, supporting diagnosis, treatment selection, and care planning for patients with both primary and metastatic CNS malignancies. By enabling NCCN guideline-recommended molecular characterization without
More news about: Belay Diagnostics
Jul 21, 2026, 10:00 ET Bracco Receives Approval in Mexico for VUEWAY® injection (gadopiclenol), Advancing Its Commitment to Lower-Dose MRI Across Global Markets
www.ClinicalTrials.gov:Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
More news about: Bracco Group
Jul 21, 2026, 10:00 ET Bracco recibe la aprobación en México para la inyección VUEWAY® (gadopiclenol), reforzando su compromiso con la resonancia magnética de baja dosis en los mercados globales.
2Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol. 2024; 59(2):124-130. 3Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based
More news about: Bracco Group
Jul 21, 2026, 01:01 ET Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
includes programs targeting PRMT5 and SOS1/RAS-pathway biology, with an initial development focus in solid tumors including lung, pancreatic, ovarian, and CNS-relevant cancers. Kaveri is focused on biomarker-driven clinical development, regulatory execution, rational combination strategies, and advancing cancer
More news about: Lupin Pharmaceuticals, Inc.
Jul 20, 2026, 20:49 ET Giải bóng đá Thôn Siêu tại Quý Châu, Trung Quốc mở ra cơ hội mới cho ngành nông nghiệp
QUÝ DƯƠNG, Trung Quốc, ngày 21 tháng 7 năm 2026 /PRNewswire/ -- Bản tin từ CNS: Tiếng reo hò tràn ngập sân bóng khi vòng bán kết Giải bóng đá Thôn Siêu (Village Super League), hay còn gọi là "Cun Chao" của Trung Quốc khởi tranh tại huyện Rongjiang, tỉnh Quý Châu, Tây Nam Trung Quốc, từ ngày 18 đến
More news about: CNS
Jul 20, 2026, 09:00 ET Cohen & Steers Appoints Erik Schneberger as Chief Marketing Officer
NEW YORK, July 20, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Erik Schneberger as Executive Vice President, Chief Marketing Officer. Based in New York, Mr. Schneberger will lead
More news about: Cohen & Steers, Inc.
Jul 17, 2026, 07:00 ET DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
removal of dysfunctional mitochondria, promoting cell health and function. Mission is currently developing small molecule drug, MTX325 (targeting the CNS) which, through inhibition of the mitochondrial DUB enzyme USP30, promotes clearance of dysfunctional mitochondria – consequently improving overall cellular
More news about: Dimerix Limited
Jul 16, 2026, 16:34 ET COHEN & STEERS REPORTS RESULTS FOR SECOND QUARTER 2026
NEW YORK, July 16, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended June 30, 2026. The earnings release along with the accompanying earnings presentation can be viewed
More news about: Cohen & Steers, Inc.
Jul 16, 2026, 09:00 ET Cohen & Steers Quality Income Realty Fund, Inc. Announces Preliminary Results of Transferable Rights Offering
https://www.cohenandsteers.com/Symbols: (NYSE: CNS, RQI)
More news about: Cohen & Steers, Inc.
Jul 16, 2026, 03:22 ET Cumulus Neuroscience präsentiert auf der AAIC-Jahrestagung 2026 Daten, die zeigen, dass eine zweiminütige digitale Aufgabe die klinischen Referenzwerte für die Vorauswahl bei Alzheimer-Studien erreicht oder übertrifft
from the CNS-101 Study (NeuLogiq®) („Domänenübergreifende digitale Endpunkte für dezentrale Alzheimer-Studien: Erfahrungen aus der CNS-101-Studie") wurde von Dr. James Rowe, Professor für kognitive Neurologie an der Universität Cambridge und leitender Prüfarzt der CNS-101-Studie, vorgestellt.
More news about: Cumulus Neuroscience
Jul 15, 2026, 12:12 ET China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable
More news about: China Pharma Holdings, Inc.
Jul 15, 2026, 11:44 ET Connected Nation launches global digital skills initiative designed to create lasting impact far beyond a world record attempt
One Connected World." is designed to create resources that will continue serving communities long after the live stream ends. All content created by CN's facilitators and partners such as
More news about: CONNECTED NATION, INC.
Jul 15, 2026, 11:18 ET A Simple Blood Test Can Now Track Metabolic Health. The American Nutrition Association Says they have the Workforce to Act on It.
of a new Policy Outlook published today in Frontiers Policy Labs by Corinne Bush, CEO of the American Nutrition Association (ANA), and Amy Smith, MS, CNS, ANA's Senior Director of Nutrition Programs & Advocacy. The piece, "
More news about: American Nutrition Association
Jul 15, 2026, 09:54 ET Cumulus Neuroscience présente, lors du congrès annuel de l'AAIC 2026, des données montrant qu'une tâche numérique de deux minutes atteint ou dépasse les critères de référence cliniques en matière de pré-sélection des participants à un essai clinique sur la maladie d'Alzheimer.
décentralisés sur la maladie d'Alzheimer : Les résultats de l'étude CNS-101 (NeuLogiq®) », a été présentée par le Dr James Rowe, professeur de neurologie cognitive à l'université de Cambridge et chercheur principal de l'étude CNS-101. Cette étude a confirmé que les évaluations cognitives et EEG réalisées
More news about: Cumulus Neuroscience
Jul 15, 2026, 08:47 ET Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
— Peer-reviewed publication details RAG-17's robust translation from "bench to bedside," validating the proprietary SCAD™ delivery platform for CNS-targeted RNAi therapies —— First-in-Human trial met primary safety endpoints with no Serious Adverse Events (SAEs); demonstrated
More news about: Ractigen Therapeutics